Advertisement
Advertisement

Read Now: News and Research From IDWeek 2014
IAS 2007: Sydney, Australia; July 22-25

Key Links:

By Topic:

Search:



The Body PRO Covers:
The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
SYDNEY, AUSTRALIA
JULY 22-25, 2007


Conference Research Highlights

More of the latest coverage >>

Featuring in-depth analysis from our team of expert faculty:

Daniel Berger, M.D. Edwin DeJesus, M.D. Joel Gallant, M.D.
Margaret Hoffman-Terry, M.D. Mark Holodniy, M.D., F.A.C.P., C.I.C. Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.

Advertisement
About This Conference

The Body PRO's coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007) includes a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on IAS 2007, please visit the conference's Web site.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories, Boehringer Ingelheim and Tibotec Pharmaceuticals.


This coverage was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

FEATURED PODCASTS
More than 25 interviews are available for you to read or listen to. To view our entire collection, click here.
Joel Gallant, M.D. Joel Gallant, M.D., M.P.H., wraps up our series of daily IAS 2007 recaps with a wide-ranging discussion of first-line therapy, options for treatment- experienced patients, drugs in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.

(10MB MP3, 24 min.)
You can also read the transcript.

Daniel Berger, M.D. Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.

(11MB MP3, 24 min.)
You can also read the transcript.

Daniel Berger, M.D. Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.

(10MB MP3, 24 min.)
You can also read the transcript.